
Release date: 2026-05-15 16:10:10 Article From: Lucius Laos Recommended: 9
Tirzepatide contains the active substance tirzepatide. It is a clear, colourless to light yellow solution for subcutaneous injection. There are six strengths: 2.5 mg/dose, 5 mg/dose, 7.5 mg/dose, 10 mg/dose, 12.5 mg/dose and 15 mg/dose. Each pen contains 2.4 mL of solution, providing 4 fixed doses (0.6 mL each) plus a priming amount. Patients should read the package leaflet carefully and report any adverse reactions promptly.
Tirzepatide is indicated for two main populations: adults, adolescents and children aged 10 years and older with type 2 diabetes mellitus, and adults with severe obesity or overweight. For type 2 diabetes, it lowers blood sugar levels only when they are too high. It may be used alone (when metformin is not suitable) or in combination with other glucose-lowering medicines (including oral drugs and/or insulin) to help control blood glucose. Additionally, Tirzepatide is used for weight management in adults with obesity or overweight, in conjunction with diet and physical activity. Eligible individuals include those with a body mass index (BMI) of 30 kg/m² or greater (severe obesity), and those with a BMI between 27 kg/m² and 30 kg/m² who have weight‑related health problems (e.g., prediabetes, type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiac dysfunction, or prior cardiovascular events). In patients with obstructive sleep apnoea and severe obesity, the medicine may be used with or without positive airway pressure therapy.
Tirzepatide acts on the appetite regulation system, helping patients reduce food intake and thereby lower body weight. In patients with type 2 diabetes, it works in a glucose‑dependent manner, lowering blood sugar only when levels are elevated, so it rarely causes hypoglycaemia (unless combined with other medications). It is important that patients continue to follow the diet and exercise advice provided by their doctor, nurse or pharmacist while using Tirzepatide. The medicine is not a substitute for a healthy lifestyle, but rather part of a comprehensive treatment plan to achieve better glycaemic control and weight management. Whether for diabetes management or weight reduction, adhering to regular dosing and follow‑up visits is key to achieving good outcomes.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3322025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5422024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3242025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3392025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3172025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3722025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3122025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2912025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643